Reliance-Based Waivers Become the Predominant Trend in In-Country Testing of Pharmaceutical Products
This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends. In the context of international harmonization of good practices and standards as well as the improved information exchange between national regulatory authorities, in-country testing is considered outdated and redundant in many cases.
Erledigte Aufgaben werden auf einer To-Do-Liste abgehakt | Image Credit: © Ralf Geithe - Stock.Adobe.com
Peer-Reviewed
Submitted: January 9, 2024.
Accepted: February 6, 2024.
Abstract
This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends. In the context of international harmonization of good practices and standards as well as the improved information exchange between national regulatory authorities, in-country testing is considered outdated and redundant in many cases. More and more countries acknowledge the limited value of in-country testing compared to the benefit of full or partial testing waivers. Analyzing the changing testing requirements, the authors find that a predominant trend is waiver schemes based on unilateral reliance on reference countries with a mature regulatory system.
Introduction
In 2015, an overview of in-country quality control (QC) testing requirements for pharmaceutical products—the term “pharmaceutical product”, or simply “product”, will be used in this article to refer to small molecules, biologicals, and/or vaccines—and data on the efficiency of this practice were published by Garbe et al. (1). Findings from this study on import testing, based on data collected from multinational pharmaceutical companies, suggested that import testing does not add significant benefits to the quality or safety of drugs, provided that the products are uninterruptedly controlled according to the globally harmonized manufacturing and distribution standards. The authors, therefore, recommended establishing more exemptions from import testing, subject to well-defined conditions, and that waiver procedures are applied where a company has demonstrated appropriate controls of manufacturing and distribution processes.
This article reviews changes in in-country testing requirements since this key publication in 2015, summarizes the evolution in the field of in-country testing, and analyzes current trends.
Background
Two categories of in-country testing form part of the considerations of the review:
- Registration testing, which is performed in conjunction with the product registration.
- Import testing, which is the repeated QC testing of pharmaceutical products entering a country, including lot release testing of vaccines and blood products.
The different categories of in-country testing and their impact are further described by Garbe et al. (1).
Both categories of re-testing raise comparable challenges with regards to technical/supply/environmental issues, efficiency, and costs. One of the main impacts of in-country testing is delayed supply of products to patients. Import testing can cause drug shortage situations (1–5) while registration testing (initial market application) can cause long delays in patient access to new medicines (6), which can damage public health.
Implications of in-country testing
Several articles on in-country testing were published since 2015 (1–6). Therein, import testing was analyzed regarding its efficiency, the associated risks, challenges, issues, and costs. Supported by real data (1), a limited value of the procedure was concluded.
Click here to read the full article.About the authors
Joerg H.O. Garbe*, joerg.garbe@roche.com, is global quality manager and policy lead, F. Hoffmann‑La Roche Ltd., Pharma Global Technical Operations, Basel, Switzerland; Tais Conti is quality unit lead and technical director, Bristol Myers Squibb, São Paulo, Brazil; Mic McGoldrick is director CMC Technical Advocacy and Policy, Merck Sharp and Dohme, LLC, Horsham, PA, USA; Maria G. Jacobs is director, Regulatory Intelligence, Pfizer Global Supply, New York, US; Philippe Juvin is chief pharmaceutical officer, Sanofi Vaccines, Lyon, France; Peter J. Mlynarczyk is quality assurance director, Merck & Co. Inc., Rahway, NJ, USA; Mark van Ooij is scientific director, Johnson & Johnson Innovative Medicine, Leiden, The Netherlands; Stephan K. Roenninger is head of External Affairs Europe, Amgen (Europe) GmbH, Rotkreuz, Switzerland; Gerald Tyers is global SME Quality Advocacy, Vaccines Global Quality, GSK, Wavre, Belgium.
*To whom all correspondence should be addressed
Article details
Pharmaceutical Technology®
Vol. 48, No. 5
May 2024
Pages: 18–28
Citation
When referring to this article, please cite it as Garbe, J.H.O.; Conti, T.; McGoldrick, M.; et al. Reliance-Based Waivers Become the Predominant Trend in In-Country Testing of Pharmaceutical Products. Pharmaceutical Technology, 2024, 48 (5) 18–28.
